ProSomnus Sleep Technologies, a leading innovator in non-CPAP obstructive sleep apnea (OSA) therapy and Smart Sleep Medicine, has achieved a significant regulatory milestone. The company announced that the U.S. Food and Drug Administration (FDA) has granted Class II 510(k) clearance for its RPMO2 OSA Device, marking a pivotal advancement in sleep disorder treatment.
A New Era in Sleep Medicine
The RPMO2 OSA Device represents the first theragnostic device specifically designed for sleep medicine, integrating precision oral appliance therapy with multi-night physiologic monitoring in a single unit. This clearance, identified under FDA K252765 with product codes DQA, LQZ, LRK, PLC, and OUG, confirms that the device meets rigorous standards for safety and effectiveness in measuring oxygen saturation (SpO2) and pulse rate.
Executive Perspectives on the Breakthrough
Len Liptak, Chief Executive Officer of ProSomnus, emphasized the importance of this development. "The FDA's clearance of the RPMO2 OSA Device marks a significant milestone for sleep medicine," Liptak stated. "By integrating safe, accurate, continuous physiologic measurement into our precision oral appliance platform, we are enabling Smart Sleep Medicine—a connected, data-driven model that helps clinicians manage sleep apnea as the personal, individualized and chronic disease it truly is."
Sung Kim, Chief Technology Officer at ProSomnus, highlighted the technological achievement. "The RPMO2 OSA Device represents years of innovation in engineering, human-centric design, and rigorous scientific validation. We set out to create a miniature, highly accurate, comfortable oximeter capable of real-world performance. FDA clearance confirms that we achieved this goal and opens the door to continuous insight into patient physiology."
Clinical Implications and Professional Endorsements
The device's clearance has significant implications for dental and medical practitioners involved in sleep apnea treatment. Mark Murphy, DDS, D.ABDSM, FAASM, ProSomnus Dental Sleep Medicine Director, commented, "Dentists play a vital role in screening and treating Obstructive Sleep Apnea. The ProSomnus RPMO2 OSA Device gives dental providers a powerful new tool—real-world data that shows how patients are responding night after night. This enables proactive, personalized care, enhanced communication with patients and physicians, and improved outcomes."
Erin Mosca, PhD, ProSomnus Director of Scientific and Medical Affairs, noted the device's potential to transform clinical practice. "The ProSomnus RPMO2 OSA Device stands to elevate the practice of sleep medicine by simplifying device titration by allowing for the use of robust, objective SpO2 data to guide device titration where previously subjective patient feedback has been used."
Adrian Williams, MD, PhD, further emphasized the device's practical benefits. "Oral Appliance Therapy is integral to the treatment of Obstructive Sleep Apnea, and oximetry is integral to its diagnosis and follow-up. The ProSomnus RPMO2 OSA Device now offers clinicians the ability to continuously and easily monitor treatment without employing additional diagnostic tools. The implications for managing such a large number of patients are self-evident."
Positioning for Future Impact
This FDA clearance positions the ProSomnus RPMO2 OSA Device as a cornerstone of what the company describes as a new Smart Sleep Medicine era. This approach is characterized by connected, patient-centric, evidence-driven OSA care that moves beyond traditional treatment models. The device's ability to provide continuous physiologic monitoring alongside therapeutic intervention represents a significant step forward in managing obstructive sleep apnea as a chronic condition requiring personalized management strategies.
The development comes at a time when sleep disorders are increasingly recognized as significant public health concerns, with obstructive sleep apnea affecting millions of people worldwide. By combining diagnostic and therapeutic functions in a single device, ProSomnus aims to streamline treatment protocols and improve patient outcomes through data-driven insights.
